• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Phastar Appoints Chris Schoonmaker as Chief Operations Officer

    Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK

    EQT Private Equity Acquires SPT Labtech from Battery Ventures

    Shimadzu Scientific Instruments Extends HQ Campus

    Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Shimadzu Scientific Instruments Extends HQ Campus

    Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills

    Batavia Enters Commercial Manufacturing Business

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK

    EQT Private Equity Acquires SPT Labtech from Battery Ventures

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    IDT Biologika

    CMC Pharmaceuticals

    Kyongbo Pharmaceutical

    Biosynth Carbosynth

    Vector Partners Limited
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    IDT Biologika

    CMC Pharmaceuticals

    Kyongbo Pharmaceutical

    Biosynth Carbosynth

    Vector Partners Limited
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Cell Therapy Industry Update: What to Expect Near-Term

    Martin Lamb of TrakCel discusses the key players, challenges, and advances in the cell therapy industry

    Related CONTENT
    • Almac Group
    • First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy
    • Tevogen Completes Tech Transfer to CDMO BioCentriq
    • Aurion Biotech Makes Strategic Investments in Manufacturing
    • Orchard Therapeutics Appoints New Leadership
    Kristin Brooks, Contract Pharma07.10.17
    Contract Pharma: Please briefly describe the current state of the cell therapy industry, the biggest players and regulatory climate.
     
    Martin Lamb: Interest in cell therapies as the 4th pillar of cancer treatment remains high, as demonstrated by the $16 billion invested between 2015-2016. Cell therapy developers were prominent at the recent major oncology conference - ASCO 2017, with the latest exciting results announced by Novartis, Kite, Bluebird/Celgene and Juno. Autologous therapies continue to dominate, with Novartis and Kite neck-and-neck in the race to be the first CAR-T to market for cancer treatment. While CAR-Ts are dominating the headlines, developers of next generation cell therapies such as those modified by CRISPR/Cas9 gene editing, therapies with built-in on/off switches, different cell/receptor types (TCRs and NKs), are also attracting impressive funding.
     
    The regulatory landscape for cell therapy products remains mixed. While initiatives such as the 21st Century Cures Act in the U.S. can be viewed as positives by the industry, the EMA’s Draft Guidance on GMP for ATMPs has received harsh criticism from various quarters, including a strongly worded letter from PIC/S, an international group comprising of Regulatory Authorities from 49 countries.
     
    CP: What are the biggest challenges the cell therapy industry faces?
     
    ML: Complex, often manual, manufacturing processes requiring skilled operators may limit the ability of cell therapies to scale to reach projected market demand. Current manufacturing processes can also take weeks, which is far from ideal for critically ill or deteriorating patients. For example, in 2016 just over 3,500 patients were treated with autologous cell therapies. This is project to exceed 200,000 over the next decade. Significant improvement will have to be made for current manufacturing processes to match this demand.
     
    Cost-of-goods, largely arising as a result of the manufacturing process, is likely to be a challenge for developers and payers alike. A CAR-T therapy is estimated to cost $150,000 for manufacturing alone – the final price to health systems is likely to be more than double this amount. For autologous therapies, there is no economy of scale – each therapy is produced on a per-patient basis.
     
    Maintaining quality and traceability of products across a complex, multi-stakeholder supply chain remains a challenge. This is especially true for autologous therapies for which it is essential that a patient’s own cellular material is returned to them for infusion. It may be possible, though resource-intensive, to track products manually during early development when only a handful of patients and sites are involved. However, such a model is unlikely to continue to be effective once products reach commercialization.
     
    Cell therapies are ‘living therapies’. Their effectiveness can be impacted by their environmental conditions through the supply chain. Logistics around transferring cellular material to manufacturing sites and back to the clinic for infusion requires stringent temperature controls. As cell therapies globalize, it will be critical to have the ability to transport shipments seamlessly across borders.

    Scheduling of activities across the supply chain is also critical in cell therapy. For example, does a clinician know that manufacturing capacity when they collect cells from a patient will be available when the cells arrive? Similarly, patients often require pre-treatment before they can receive cell therapy, so knowledge of the date a therapy will be available for infusion is just as important.

    CP: In what areas have advances been made to help overcome these challenges?
     
    ML: Development of automated, closed system equipment, such as Miltenyi’s Prodigy system, to manufacturer cell therapies is removing the need for lengthy, highly manual processes executed by highly skilled operatives. Automated systems have the potential to ‘democratise’ cell therapies by increasing the number of operators and centers capable of handling the manufacturing process.
     
    The introduction of automation can also reduce the risk of lost products elsewhere in the supply chain. For example, inconsistent thawing of frozen cellular material can negatively impact on product integrity. The introduction of automated thawing devices can reduce the risk of product loss during thawing.

    IT solutions have been developed that provide support in these areas by tracking product quality across the supply chain. TrakCel’s platform provides full needle-needle tracking of cellular material, includes an integral scheduler to support alignment of supply chain activities, and gives cell therapy developers the ability to incorporate product-specific workflows into the system ensuring all those involved in the supply chain execute activities in a consistent, compliant manner. Furthermore, the platform’s integration with third party systems, from logistics providers, manufacturing sites to clinics, provides a full end-end view of the supply chain, allowing points of failure to be identified and processes optimized to seal off and prevent future issues.
     
    Cryogenic freezing technologies are also improving. For example, cell preservation media designed for cryogenic freezing can help reduce cell loss as a result of this process. Advanced cryogenic shipping systems, such as Savsu’s EVO shipper, are helping control risk of loss during shipment by allowing real time tracking of temperature and location. Cryogenic freezing of cells can help introduce some flexibility when scheduling patient treatment.
     
    CP: How do technology solutions play into various stages of cell therapy development, manufacture and delivery processes?
     
    ML: Technology plays a critical role throughout the cell therapy delivery process, and will grow in importance as cell therapies are commercialized. For example, patients identified as suitable candidates for cell therapy can be captured in patient registries or systems such as CRM. Once commercialized, and given the likely high price of cell therapies, payers are likely to need to approve patients for treatment before this can begin and this process can also be system based.
     
    Once the patient begins treatment, it is necessary to assign a unique identification to the patient, which will be used to track their cells throughout the supply chain. Established systems such as ERP, MES and QMS can be used to track the product’s process through manufacturing and logistics, with systems such as LIMS used to capture analytical test results to verify product quality before it is deemed suitable for use in patients. Equipment itself can capture data critical to a treatment’s integrity – for example, cell count and start/finish times.
     
    Finally, once a therapy is commercialized, payment models for these expensive treatments are likely to involve long follow-up periods, which are also likely to involve capturing key clinical milestones through IT systems such as EDC, ePRO and treatment centres’ own systems.
     
    While technology supports the entire cell therapy delivery process, it is important to note that this data is currently captured by separate systems. It is becoming steadily more important to provide cell therapy developers with a full end-end chain or custody report covering what was done, what material was used, when and by whom it is essential to implement a system that combines data from these disparate sources. This can provide product owners, physicians, regulators and patients with confidence in the quality of the product before it is used. Moreover, capturing this data in a single system gives cell therapy developers the opportunity to use data to optimize their processes, favourably impacting on the cost of goods. It also means they can concentrate resources on what they are, by default, good at – developing cell therapies, and not using crucial resources on logistics.
     


     
    Martin Lamb joined TrakCel as executive vice president in March 2017. Martin is responsible for all commercial sales and marketing activities within the company. He has held a variety of senior business development roles in leading contract development and manufacturing organisations throughout his 25-year career in the pharmaceutical and biotechnology industry. Prior to joining TrakCel, Martin was director of European business development for Catalent Pharma Services. During his time as Vice President of Global Business Development at the Almac Group, Martin helped the group’s clinical trial supply business grow from a niche service offering to a major business with over 1,500 staff internationally.
    Related Searches
    • GMP
    • cell therapies
    • novartis
    • mes
    Suggested For You
    Almac Group Almac Group
    First Patient is Dosed with Triumvira First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy
    Tevogen Completes Tech Transfer to CDMO BioCentriq Tevogen Completes Tech Transfer to CDMO BioCentriq
    Aurion Biotech Makes Strategic Investments in Manufacturing Aurion Biotech Makes Strategic Investments in Manufacturing
    Orchard Therapeutics Appoints New Leadership Orchard Therapeutics Appoints New Leadership
    PBS Biotech Scales-Up Manufacturing Solutions for Cell Therapies PBS Biotech Scales-Up Manufacturing Solutions for Cell Therapies
    Innoforce Expands Cell and Gene Therapy Capabilities Innoforce Expands Cell and Gene Therapy Capabilities
    Lykan and Vineti Form Cell Therapy Agreement Lykan and Vineti Form Cell Therapy Agreement
    Discovery Life Sciences Appoints Cell & Gene Therapy CTO Discovery Life Sciences Appoints Cell & Gene Therapy CTO
    Lonza, Sheba Medical Center Leverage Cocoon Platform for Cell Therapy Lonza, Sheba Medical Center Leverage Cocoon Platform for Cell Therapy
    BioLife Solutions Acquires Sexton Biotechnologies BioLife Solutions Acquires Sexton Biotechnologies
    Veklury Drives 2Q Growth for Gilead Veklury Drives 2Q Growth for Gilead
    TCR2 Therapeutics Appoints Chief Technical Officer TCR2 Therapeutics Appoints Chief Technical Officer
    Thermo Fisher Scientific Launches Heracell Vios CR CO2 Incubator Thermo Fisher Scientific Launches Heracell Vios CR CO2 Incubator
    BioNTech to Acquire Kite’s TCR Cell Therapy Platform and Mfg. Facility BioNTech to Acquire Kite’s TCR Cell Therapy Platform and Mfg. Facility

    Related Content

    • Formulation Development
      Almac Group

      Almac Group

      ...
      Kerry Lyle, Mrs 01.07.22

    • Breaking News | Clinical Trials
      First Patient is Dosed with Triumvira

      First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy

      TAC01-HER2 was developed for the treatment of HER2-overexpressing cancers.
      09.21.21

    • Bio News | Breaking News | Clinical Trial Materials | Collaborations & Alliances | Industry News | Scale-up/Technology Transfer
      Tevogen Completes Tech Transfer to CDMO BioCentriq

      Tevogen Completes Tech Transfer to CDMO BioCentriq

      Reaches commercial manufacturing readiness milestone for its investigational COVID-19 therapy TVGN-489.
      09.16.21


    • Breaking News | Industry News | Promotions & Moves
      Aurion Biotech Makes Strategic Investments in Manufacturing

      Aurion Biotech Makes Strategic Investments in Manufacturing

      Appoints Tim Largen as VP of manufacturing to drive cell therapy production strategy and direct collaborations with leading CDMOs.
      09.14.21

    • Breaking News | Promotions & Moves
      Orchard Therapeutics Appoints New Leadership

      Orchard Therapeutics Appoints New Leadership

      Names new chief scientific officer, chief technical officer and chief medical officer.
      09.09.21

      Loading, Please Wait..
      Trending
      • Regulatory Report: Analytical Procedure Development
      • Pierre Fabre And Lonza Enter Manufacturing Agreement
      • Pfizer, BioNTech Adapt COVID Vax Against Omicron
      • Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
      • Shimadzu Scientific Instruments Extends HQ Campus
      Breaking News
      • Phastar Appoints Chris Schoonmaker as Chief Operations Officer
      • Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK
      • EQT Private Equity Acquires SPT Labtech from Battery Ventures
      • Shimadzu Scientific Instruments Extends HQ Campus
      • Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Kensing Acquires Vitae Naturals
      CoQ10 and Royal Jelly Supplementation May Improve High Intensity Exercise
      Shiitake Mushroom Extract Appears Helpful in HPV Infections
      Coatings World

      Latest Breaking News From Coatings World

      Sheboygan Paint Company Adds Rosey Malchow as Customer Experience Manager
      PPG to Announce Second Quarter 2022 Results July 21
      Evonik Unveils Range of Sustainable Liquid Polybutadienes
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Researchers Develop New Apparatus for the Treatment of Cardiovascular Diseases
      NovaXS Unveils New Prototype of Needle-Free Injection Therapy Smart Medical Device
      Meddux Opens New Facility in Boulder, Colorado
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Phastar Appoints Chris Schoonmaker as Chief Operations Officer
      Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK
      EQT Private Equity Acquires SPT Labtech from Battery Ventures
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Highlights from Paris Packaging Week
      Walgreens Boots Alliance Decides Not to Sell Boots and No7 Beauty Company Businesses
      WWP Beauty Unveils New Packaging Collections in Collaboration with Eastman
      Happi

      Latest Breaking News From Happi

      Evonik Holds Groundbreaking Ceremony for Commercial Rhamnolipid Production Facility
      CHT USA Hosts Groundbreaking Ceremony for $20 Million US Headquarters Expansion
      Azelis Expands Global Flavors & Fragrances Platform with Acquisition in India
      Ink World

      Latest Breaking News From Ink World

      Temporary Content Title
      Amcor Lift-Off Initiative Shortlists Start-ups for Seed Funding
      Barentz Highlights Lincoln MFG’s New ISO 9001:2015 Certification
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Sibress launches FADS3D flexo plate measuring device
      Mike Brown appointed VP for Davis-Standard’s Canadian operations
      Constantia Flexibles introduces chemical resistant recycle-ready laminate
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Suominen Launches Hydraspun Reserve
      Richard Knowlson Receives Lifetime Technical Achievement Award
      Skylark Launches Thicker Label Closure Technology in North American
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Tecomet Appoints Bill Dow as President & CEO
      Medacta, InSilicoTrials Partner on Orthopedic Device Development
      Researchers Develop Microfluidic Sensors to Improve Implant Survival Rates
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Avery Dennison Launches New Dual-Frequency RFID Inlay
      Avery Dennison Highlights New Approach to Apparel with ADX Lab
      trinamiX Face Authentication Protects Users from Fraud Attacks During Mobile Payments

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login